Press Releases

Press Releases

July 30, 2019
CytomX Therapeutics to Announce Second Quarter 2019 Financial Results
-Teleconference Scheduled for August 7, 2019, at 5:00 p.m. ET- SOUTH SAN FRANCISCO, Calif. , July 30, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics
Additional Formats
May 28, 2019
CytomX Therapeutics to Present at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif. , May 28, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, announced
Additional Formats
May 15, 2019
CytomX Therapeutics Announces Presentations at 2019 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif. , May 15, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced
Additional Formats
May 9, 2019
CytomX Therapeutics Announces First Quarter 2019 Financial Results
Company to Host a Conference Call Today, May 9, 2019, at 5:00 p.m. EDT / 2:00 p.m. PDT SOUTH SAN FRANCISCO, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational
Additional Formats
May 2, 2019
CytomX Therapeutics to Announce First Quarter 2019 Financial Results
-Teleconference Scheduled for May 9, 2019, at 5:00 p.m. ET- SOUTH SAN FRANCISCO, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on
Additional Formats
Displaying 1 - 10 of 21